Heart failure in adult congenital heart disease

Joel Mc Larry, Craig Broberg

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Abstract

    As the adult congenital heart disease population expands and ages due to the success of early diagnosis and intervention, many of those individuals have or will develop myocardial dysfunction and the symptoms of heart failure. Given the incidence of myocardial dysfunction in this population today, expectations are that future numbers of individuals with heart failure over the coming decades may be overwhelming. The clinical characteristics of the adults with congenital heart disease population, in general, are similar to other heart failure populations, including biomarker elevation, exercise intolerance, arrhythmia, and mortality. The etiology of heart failure in adults with congenital heart disease is often multifactorial, resulting from chronic adverse loading conditions, fetal and neonatal events, abnormal ventricular architecture and geometry, and abnormal coronary perfusion, each leading to a final common pathway of myocardial fibrosis. Abundant data demonstrate clear benefit of pharmacotherapy in heart failure from acquired heart disease, including ACE inhibitors, angiotensin receptor blockers, beta-blockers, and aldosterone antagonists. However, in adults with congenital heart disease, the benefit of these medicines has not been clearly shown. As heart failure progresses in this population, ventricular assist devices and cardiac transplantation are being increasingly used; however, experience in utilizing them in adults with congenital heart disease still remains limited.

    Original languageEnglish (US)
    Title of host publicationPediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care
    PublisherSpringer-Verlag London Ltd
    Pages2695-2711
    Number of pages17
    ISBN (Print)9781447146193, 9781447146186
    DOIs
    StatePublished - Jan 1 2014

    Fingerprint

    Heart Diseases
    Heart Failure
    Population
    Mineralocorticoid Receptor Antagonists
    Heart-Assist Devices
    Angiotensin Receptor Antagonists
    Heart Transplantation
    Angiotensin-Converting Enzyme Inhibitors
    Cardiac Arrhythmias
    Early Diagnosis
    Fibrosis
    Perfusion
    Biomarkers
    Drug Therapy
    Mortality
    Incidence

    Keywords

    • Arrhythmias
    • Biomarkers
    • BNP
    • Exercise intolerance
    • Heart failure in ACHD
    • Heart transplantation
    • Ischemia
    • Mechanism of heart failure
    • Medical therapy
    • Morbidity
    • Mortality
    • Myocardial fibrosis
    • Natriuretic peptides
    • Prevalence
    • Single-ventricle patient
    • Systemic right ventricle
    • Tetralogy of Fallot
    • Ventricular assist device

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Mc Larry, J., & Broberg, C. (2014). Heart failure in adult congenital heart disease. In Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care (pp. 2695-2711). Springer-Verlag London Ltd. https://doi.org/10.1007/978-1-4471-4619-3_194

    Heart failure in adult congenital heart disease. / Mc Larry, Joel; Broberg, Craig.

    Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care. Springer-Verlag London Ltd, 2014. p. 2695-2711.

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Mc Larry, J & Broberg, C 2014, Heart failure in adult congenital heart disease. in Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care. Springer-Verlag London Ltd, pp. 2695-2711. https://doi.org/10.1007/978-1-4471-4619-3_194
    Mc Larry J, Broberg C. Heart failure in adult congenital heart disease. In Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care. Springer-Verlag London Ltd. 2014. p. 2695-2711 https://doi.org/10.1007/978-1-4471-4619-3_194
    Mc Larry, Joel ; Broberg, Craig. / Heart failure in adult congenital heart disease. Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care. Springer-Verlag London Ltd, 2014. pp. 2695-2711
    @inbook{d88cfe02c54146aab9885936275198cb,
    title = "Heart failure in adult congenital heart disease",
    abstract = "As the adult congenital heart disease population expands and ages due to the success of early diagnosis and intervention, many of those individuals have or will develop myocardial dysfunction and the symptoms of heart failure. Given the incidence of myocardial dysfunction in this population today, expectations are that future numbers of individuals with heart failure over the coming decades may be overwhelming. The clinical characteristics of the adults with congenital heart disease population, in general, are similar to other heart failure populations, including biomarker elevation, exercise intolerance, arrhythmia, and mortality. The etiology of heart failure in adults with congenital heart disease is often multifactorial, resulting from chronic adverse loading conditions, fetal and neonatal events, abnormal ventricular architecture and geometry, and abnormal coronary perfusion, each leading to a final common pathway of myocardial fibrosis. Abundant data demonstrate clear benefit of pharmacotherapy in heart failure from acquired heart disease, including ACE inhibitors, angiotensin receptor blockers, beta-blockers, and aldosterone antagonists. However, in adults with congenital heart disease, the benefit of these medicines has not been clearly shown. As heart failure progresses in this population, ventricular assist devices and cardiac transplantation are being increasingly used; however, experience in utilizing them in adults with congenital heart disease still remains limited.",
    keywords = "Arrhythmias, Biomarkers, BNP, Exercise intolerance, Heart failure in ACHD, Heart transplantation, Ischemia, Mechanism of heart failure, Medical therapy, Morbidity, Mortality, Myocardial fibrosis, Natriuretic peptides, Prevalence, Single-ventricle patient, Systemic right ventricle, Tetralogy of Fallot, Ventricular assist device",
    author = "{Mc Larry}, Joel and Craig Broberg",
    year = "2014",
    month = "1",
    day = "1",
    doi = "10.1007/978-1-4471-4619-3_194",
    language = "English (US)",
    isbn = "9781447146193",
    pages = "2695--2711",
    booktitle = "Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care",
    publisher = "Springer-Verlag London Ltd",

    }

    TY - CHAP

    T1 - Heart failure in adult congenital heart disease

    AU - Mc Larry, Joel

    AU - Broberg, Craig

    PY - 2014/1/1

    Y1 - 2014/1/1

    N2 - As the adult congenital heart disease population expands and ages due to the success of early diagnosis and intervention, many of those individuals have or will develop myocardial dysfunction and the symptoms of heart failure. Given the incidence of myocardial dysfunction in this population today, expectations are that future numbers of individuals with heart failure over the coming decades may be overwhelming. The clinical characteristics of the adults with congenital heart disease population, in general, are similar to other heart failure populations, including biomarker elevation, exercise intolerance, arrhythmia, and mortality. The etiology of heart failure in adults with congenital heart disease is often multifactorial, resulting from chronic adverse loading conditions, fetal and neonatal events, abnormal ventricular architecture and geometry, and abnormal coronary perfusion, each leading to a final common pathway of myocardial fibrosis. Abundant data demonstrate clear benefit of pharmacotherapy in heart failure from acquired heart disease, including ACE inhibitors, angiotensin receptor blockers, beta-blockers, and aldosterone antagonists. However, in adults with congenital heart disease, the benefit of these medicines has not been clearly shown. As heart failure progresses in this population, ventricular assist devices and cardiac transplantation are being increasingly used; however, experience in utilizing them in adults with congenital heart disease still remains limited.

    AB - As the adult congenital heart disease population expands and ages due to the success of early diagnosis and intervention, many of those individuals have or will develop myocardial dysfunction and the symptoms of heart failure. Given the incidence of myocardial dysfunction in this population today, expectations are that future numbers of individuals with heart failure over the coming decades may be overwhelming. The clinical characteristics of the adults with congenital heart disease population, in general, are similar to other heart failure populations, including biomarker elevation, exercise intolerance, arrhythmia, and mortality. The etiology of heart failure in adults with congenital heart disease is often multifactorial, resulting from chronic adverse loading conditions, fetal and neonatal events, abnormal ventricular architecture and geometry, and abnormal coronary perfusion, each leading to a final common pathway of myocardial fibrosis. Abundant data demonstrate clear benefit of pharmacotherapy in heart failure from acquired heart disease, including ACE inhibitors, angiotensin receptor blockers, beta-blockers, and aldosterone antagonists. However, in adults with congenital heart disease, the benefit of these medicines has not been clearly shown. As heart failure progresses in this population, ventricular assist devices and cardiac transplantation are being increasingly used; however, experience in utilizing them in adults with congenital heart disease still remains limited.

    KW - Arrhythmias

    KW - Biomarkers

    KW - BNP

    KW - Exercise intolerance

    KW - Heart failure in ACHD

    KW - Heart transplantation

    KW - Ischemia

    KW - Mechanism of heart failure

    KW - Medical therapy

    KW - Morbidity

    KW - Mortality

    KW - Myocardial fibrosis

    KW - Natriuretic peptides

    KW - Prevalence

    KW - Single-ventricle patient

    KW - Systemic right ventricle

    KW - Tetralogy of Fallot

    KW - Ventricular assist device

    UR - http://www.scopus.com/inward/record.url?scp=84961340912&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84961340912&partnerID=8YFLogxK

    U2 - 10.1007/978-1-4471-4619-3_194

    DO - 10.1007/978-1-4471-4619-3_194

    M3 - Chapter

    AN - SCOPUS:84961340912

    SN - 9781447146193

    SN - 9781447146186

    SP - 2695

    EP - 2711

    BT - Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care

    PB - Springer-Verlag London Ltd

    ER -